TIB200 is a topical 10% ibuprofen gel for pain relief that utilises Futura's DermaSys® technology. DermaSys® enables a fast onset of relief at the site of pain and the potential for improved patient benefit by reducing the dosing frequency from three to four times daily to twice daily.

How TIB200 works​

Application of gel with ibuprofen

Combination of solvents, including volatile solvents

Seconds later

Volatile solvents evaporate, leaving the remaining solvent supersaturated with ibuprofen.
The supersaturation powerfully drives ibuprofen through the skin

Minutes later

Ibuprofen penetrates the skin rapidly to reach the site of action.
Targeted delivery and sustained release

Compelling clinical data showing efficacy and safety profile

In early in vitro studies and in an in vivo clinical study DermaSys® showed significant superiority in terms of skin penetration of ibuprofen. TIB200, a topical gel combining the well-known analgesic ibuprofen with the DermaSys® delivery system, has been shown to achieve up to twenty times higher penetration through human skin compared against other commercially available topical ibuprofen gels.

In a clinical study to assess the efficacy and safety against a market-leading ibuprofen gel, oral ibuprofen as well as a placebo gel, TIB200 not only achieved its primary efficacy endpoint against placebo but also outperformed both the topical and oral comparators.

Improved permeation compared to market leaders at same dosage

Commercial strategy

TIB200 has attracted considerable interest from pharmaceutical and consumer healthcare companies. We continue to be in discussions regarding potential regional licensing deals. EU regulators require a placebo controlled efficacy study prior to EU regulatory filing. Futura made the strategic decision to require partner commitment before progressing this clinical expenditure.